Compare · LEGN vs XBIO

LEGN vs XBIO

Side-by-side comparison of Legend Biotech Corporation (LEGN) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LEGN and XBIO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LEGN is the larger of the two at $2.97B, about 904.1x XBIO ($3.3M).
  • LEGN has been more active in the news (11 items in the past 4 weeks vs 6 for XBIO).
  • LEGN has more recent analyst coverage (25 ratings vs 0 for XBIO).
MetricLEGNXBIO
Company
Legend Biotech Corporation
Xenetic Biosciences Inc.
Price
-
-
Market cap
$2.97B
$3.3M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
11
6
Recent ratings
25
0
LEGN

Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

XBIO

Xenetic Biosciences Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Latest LEGN

Latest XBIO